Colchicine toxicityMANAGEMENT

TOXICOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

533 items

☷ Legend

01Approach to the Critical Patient/attcp47

Immediate priorities

›Colchicine overdose is a lethal poisoning with a deceptively benign early phase

›Patients frequently appear well for the first several hours after ingestion

›Normal initial vital signs and normal initial laboratory results do not exclude a fatal ingestion

›Any reported ingestion above 0.5 mg/kg is potentially life-threatening irrespective of initial appearance

›Ingested dose in mg/kg estimated early because it drives disposition and prognosis

›Below 0.5 mg/kg predicts a predominantly gastrointestinal course with death unusual

›0.5 to 0.8 mg/kg predicts bone marrow failure with mortality around 10%

›Above 0.8 mg/kg predicts cardiovascular collapse and is frequently fatal, with reported mortality above 50%

›Poison center or medical toxicologist contacted at first suspicion

›Early consultation guides decontamination, monitoring duration, and transfer

›No widely available antidote exists, so supportive escalation must be planned in advance

›Phase of illness identified on arrival

›Phase 1, first 24 hours, is gastrointestinal fluid loss and hypovolemia

›Phase 2, day 1 to day 7, is multi-organ failure, marrow suppression, and sudden cardiac death

›Phase 3, after day 7, is recovery with rebound leukocytosis and delayed alopecia

›Disposition default is admission for anyone with a credible toxic ingestion

›Deterioration is often abrupt and follows an asymptomatic interval

›Emergency department discharge is only for clearly sub-toxic exposures after a defined observation period

Resuscitation and hemodynamic control

›Airway management anticipating collapse

›Early intubation for declining mental status, intractable vomiting, or acute respiratory distress syndrome

›Vasopressor prepared and running before induction because peri-intubation arrest is common

›Ketamine 1 to 2 mg/kg IV is the preferred induction agent for hemodynamic stability

›Oxygenation and ventilation targets

›SpO2 94 to 98% for most patients

›SpO2 88 to 92% in known chronic hypercapnic respiratory disease

›Lung-protective ventilation with tidal volume 6 ml/kg predicted body weight once acute respiratory distress syndrome develops

02History/hx43

Exposure and dose history

›Total quantity ingested, in milligrams and in tablets, cross-checked against the prescription and pharmacy records

›Tablet strengths are commonly 0.5 mg or 0.6 mg

›Dose per kilogram calculated from a measured or reliably stated body weight

›Time of ingestion and whether the dose was taken all at once or staggered

›Staggered ingestion can delay and prolong the toxic course

›An asymptomatic interval of several hours is expected and is not reassuring

›Intent of the exposure

›Deliberate self-poisoning, therapeutic error, or pediatric exploratory ingestion

›Psychiatric history and risk assessment where the ingestion was intentional

›Source of the drug

›The patient's own prescription for gout, familial Mediterranean fever, pericarditis, or Behcet disease

›A household member's supply, particularly in pediatric ingestion

›Plant material containing colchicine, such as autumn crocus, Colchicum autumnale, or glory lily, Gloriosa superba

›Symptom timeline since ingestion

›Onset of nausea, vomiting, diarrhea, and abdominal pain

›Any syncope, palpitations, dyspnea, reduced urine output, bleeding, or confusion

Formulation, coingestants, and prior course

›Coingestants that change the resuscitation

›Acetaminophen and salicylate concentrations because of their frequency in intentional overdose

›Alcohol, sedatives, and other cardiotoxic agents

›Antimotility or analgesic self-treatment already taken

›Loperamide or opioids taken for the diarrhea, which mask fluid losses and promote ileus

›Nonsteroidal anti-inflammatory drugs taken for pain, which add renal and gastrointestinal injury

›Care received before arrival

›Prehospital fluids, antiemetics, or activated charcoal

›Transfer from a facility without toxicology or critical care support

›Prior episodes and baseline organ function

03Physical Exam/exam37

Vital signs and general appearance

›Serial vital signs because early normality is common and misleading

›Resting tachycardia as the earliest objective sign of volume loss

›Hypotension and a narrowed pulse pressure signaling established shock

›Volume status

›Dry mucous membranes, reduced skin turgor, capillary refill beyond 2 seconds

›Urine output below 0.5 ml/kg/h, interpreted against baseline in chronic kidney disease or dialysis dependence

›Temperature

›Low-grade fever from tissue injury and leukocytosis

›Later hypothermia as a marker of shock and marrow failure

›Mental status

›Initially normal, later lethargy, confusion, or coma

›A focal neurological deficit should prompt reconsideration of an alternative diagnosis

Phase 1 gastrointestinal findings

›Profuse vomiting and watery, sometimes bloody, diarrhea

›Quantified fluid losses recorded to guide replacement

›Orthostatic vital sign change where the patient can sit or stand safely

›Diffuse abdominal tenderness without peritonism

›Guarding or rebound raising concern for an alternative surgical cause

›Absent bowel sounds indicating ileus and contraindicating multi-dose charcoal

›Signs of significant dehydration

›Sunken eyes, tachypnea from metabolic acidosis, cool peripheries

›Weight loss against a recent known weight where available

Phase 2 multi-organ findings

›Cardiovascular

›New gallop, raised jugular venous pressure, and pulmonary crackles from toxic cardiomyopathy

›Cardiogenic shock with cold, poorly perfused peripheries despite fluid loading

›Arrhythmia or bradycardia from conduction system involvement

04Differential Diagnosis/ddx44

Toxicologic mimics

›Amatoxin-containing mushroom poisoning

›Shares the biphasic pattern of delayed severe gastroenteritis then multi-organ failure

›Hepatic failure dominates, whereas early cardiovascular collapse favors colchicine

›Iron poisoning

›Early hemorrhagic gastroenteritis, hypovolemic shock, then metabolic acidosis and hepatotoxicity

›Radio-opaque tablets on abdominal radiograph and a raised serum iron concentration

›Arsenic and other heavy metal poisoning

›Severe watery diarrhea, third-space losses, and cardiovascular collapse

›QT prolongation early and peripheral neuropathy later

›Cardioactive drug overdose

›Calcium channel blocker, beta blocker, or digoxin toxicity presenting with shock and bradyarrhythmia

›Diltiazem and verapamil are also colchicine interaction culprits, so combined toxicity is possible

›Toxic alcohols, salicylates, and theophylline

›Vomiting with a high anion gap metabolic acidosis

›Distinguished by specific concentrations and osmolar gap

›Ricin or abrin ingestion from castor bean or rosary pea seeds

›Delayed hemorrhagic gastroenteritis and multi-organ failure

Non-toxicologic mimics

›Septic shock, including a source-unknown presentation with gastroenteritis

›Early leukocytosis in colchicine toxicity can be misread as infection

›Concurrent sepsis is not excluded and empirical antibiotic cover may still be warranted

›Infectious gastroenteritis with severe dehydration

›Common and usually self-limiting, but cannot explain progressive multi-organ failure

›Diabetic ketoacidosis and other metabolic emergencies

›Vomiting, abdominal pain, tachypnea, and shock overlap

›Excluded by glucose, ketones, and a blood gas

›Mesenteric ischemia

05Laboratory Tests/lt36

Baseline panel

›Full blood count with differential and blood film

›Early neutrophil leukocytosis is expected and is a toxicity marker, not proof of infection

›The baseline value anchors interpretation of the later nadir

›Urea, creatinine, and electrolytes

›Acute kidney injury from hypovolemia, then direct toxicity and rhabdomyolysis

›Potassium above 5.5 mmol/l from acute kidney injury and cellular injury

›Calcium, magnesium, and phosphate

›Ionized calcium below 1.1 mmol/l and phosphate below 0.8 mmol/l are characteristic early

›Magnesium below 0.7 mmol/l compounds arrhythmia risk

›Venous or arterial blood gas with lactate

›Lactate above 2 mmol/l, and above 4 mmol/l indicating severe hypoperfusion

›High anion gap metabolic acidosis

›Glucose

›Hypoglycemia below 3.9 mmol/l from hepatic involvement and poor intake, then stress hyperglycemia

›Acetaminophen and salicylate concentrations in any intentional overdose

Markers of multi-organ injury

›Muscle and cardiac markers

›Creatine kinase and urine myoglobin for rhabdomyolysis

›Troponin for myocardial injury, tracking with toxic cardiomyopathy

›Hepatic and metabolic markers

›Aminotransferases, bilirubin, and lactate dehydrogenase for hepatocellular injury

›Lipase where abdominal pain could represent pancreatitis

›Coagulation and transfusion readiness

›Coagulation screen with fibrinogen and D-dimer for disseminated intravascular coagulation

›Falling fibrinogen below 1.5 g/l and falling platelets are early warnings

›Group and screen, anticipating transfusion in phase 2

06Diagnostic Tests/dt38

Scoring Systems

›No validated colchicine-specific severity score exists

›Prognosis is stratified by ingested dose in mg/kg

›Below 0.5 mg/kg, 0.5 to 0.8 mg/kg, and above 0.8 mg/kg define increasing mortality

›General critical care scores used for trajectory rather than triage

›Sequential organ failure assessment for cumulative organ dysfunction

›APACHE II on intensive care admission

›Poisoning severity score applied descriptively

›Useful for communication and audit rather than as a management threshold

›Does not replace serial clinical and laboratory reassessment

MRI

›Not indicated for the diagnosis or acute management of colchicine toxicity

›Reserved for unexplained neurological deficit once the patient is stable

›Cardiac MRI has a later role to characterize residual cardiomyopathy in survivors

›Practical constraints in the acute phase

›Hemodynamic instability and ventilator dependence usually preclude MRI

›Imaging is deferred until it will change management

›CT of the abdomen and pelvis with contrast when a surgical abdomen cannot be excluded clinically

›Evaluates mesenteric ischemia, perforation, and pancreatitis

›A normal study supports colchicine-driven gastrointestinal injury

›CT of the head for seizure, focal deficit, or unexplained coma

›Also assesses for intracranial hemorrhage when disseminated intravascular coagulation or thrombocytopenia is present

›CT pulmonary angiography where acute respiratory distress syndrome and pulmonary embolism are hard to separate

›Weighed against contrast nephrotoxicity in established acute kidney injury

Ultrasound

›Focused cardiac ultrasound at the bedside

›Serial assessment of left ventricular function to detect evolving toxic cardiomyopathy

07Disposition/dispo28

Intensive care admission and level of care

›Intensive care admission for any ingestion at or above 0.5 mg/kg

›Also for hemodynamic instability, arrhythmia, respiratory compromise, acute kidney injury, or cytopenia

›Also for therapeutic-dose toxicity with a clear interacting drug and evolving organ dysfunction

›High-dependency or monitored bed for lower-risk ingestions still within the observation window

›Continuous telemetry, hourly vital signs, and strict fluid balance

›Low threshold to step up given the pattern of abrupt deterioration

›Anticipated deterioration timeline

›Cardiovascular collapse typically occurs between 24 and 72 hours

›Marrow nadir occurs at day 4 to 7, after the point at which many poisonings would otherwise be discharged

Transfer to a toxicology and ECMO-capable center

›Early transfer, before decompensation, for any ingestion above 0.8 mg/kg or any early cardiotoxicity

›Venoarterial extracorporeal membrane oxygenation is the main salvage option for refractory cardiogenic shock

›Move the patient while still stable enough to travel safely

›Transfer criteria for a non-tertiary emergency department

›No on-site intensive care, medical toxicology, or extracorporeal support

›Rising lactate, falling blood pressure, new arrhythmia, or a large stated ingestion

›Communication with the receiving team

›Send dose estimate in mg/kg, timeline, serial observations, and all results with the patient

›Involve the receiving intensivist and toxicologist before departure

Observation, medical clearance, and consultations

›Minimum observation for an apparently minor ingestion

›At least 8 to 12 hours of monitoring with serial examination and repeat bloods

›Discharge only if asymptomatic with normal repeat counts, biochemistry, calcium, and ECG, and a reliable dose history below 0.5 mg/kg

›Any gastrointestinal symptom attributable to colchicine mandates admission

›Consultations

›Medical toxicology or poison center for every case

›Critical care for admission and organ support

08Treatment/t117

Gastrointestinal decontamination

›Activated charcoal 1 g/kg orally or by nasogastric tube, maximum 50 g

›Given when presentation is within 1 to 2 hours and the airway is intact or protected

›A single dose is still reasonable later given the lethality of the poisoning

›Withheld for obtundation or active vomiting without a secured airway because charcoal aspiration causes severe pneumonitis

›Multi-dose activated charcoal 25 g, about 0.5 g/kg, every 2 to 4 hours

›Targets enterohepatic recirculation of colchicine

›Each dose preceded by a check of bowel sounds, distension, and nasogastric residual volume

›Stopped for ileus or bowel obstruction

›Whole bowel irrigation with polyethylene glycol electrolyte solution 1 to 2 l/h in adults

›Considered only for very large ingestions or plant material with a protected airway and no ileus

›Not a routine measure and stopped if distension or vomiting develops

›Antimotility agents such as loperamide 2 mg orally not used to control the diarrhea

›They do not address mucosal injury and promote ileus and toxin retention

Fluid resuscitation and electrolyte correction

›Isotonic crystalloid, a balanced solution preferred

›Adults 250 to 500 ml boluses, children 10 to 20 ml/kg boluses, reassessed after each

›Verify against current pediatric guideline before use

›Titrated to perfusion, lactate clearance, and urine output of at least 0.5 ml/kg/h

›Urine output target interpreted against baseline in chronic kidney disease or dialysis dependence

›Escalation to vasopressors rather than continued large-volume fluids once dynamic measures show fluid unresponsiveness

›Hypocalcemia correction

›Calcium gluconate 10% 10 to 20 ml, that is 1 to 2 g, IV over 10 minutes for symptomatic hypocalcemia or a hyperkalemic ECG change

›Repeat dosing guided by ionized calcium

›Hypomagnesemia correction

›Magnesium sulfate 2 g IV over 15 minutes, aiming to keep magnesium above 1.0 mmol/l when there is arrhythmia

›Hypophosphatemia and hypokalemia correction

›Potassium chloride 10 mmol/h IV with cardiac monitoring, adjusted for renal function

›Sodium or potassium phosphate 15 to 30 mmol IV over 6 to 12 hours for phosphate below 0.3 mmol/l or symptoms

›Caution once phase 2 begins

›Capillary leak and toxic cardiomyopathy convert fluid tolerance into fluid harm

›Frequent reassessment with lung and inferior vena cava ultrasound

Vasoactive and inotropic support

›Norepinephrine as the first-line vasopressor

›Start 0.05 mcg/kg/min IV infusion

›Titrate every 5 to 10 minutes to a mean arterial pressure of at least 65 mmHg

›Switch to smaller increments as the target is approached to avoid overshoot

›Usual effective ceiling around 1 mcg/kg/min before adding a second agent

›Mean arterial pressure target 75 to 85 mmHg in long-standing hypertension, and a lower target is acceptable in chronic hypotension or end-stage renal disease on dialysis

›Vasopressin 0.03 units/min IV as a fixed-rate second agent

›Not titrated

›Added to spare escalating catecholamine doses

›Inotrope for the cardiogenic component

›Dobutamine 2.5 to 5 mcg/kg/min IV, titrated to a maximum of 20 mcg/kg/min

›Reduced or withdrawn if it worsens tachyarrhythmia or hypotension

›Epinephrine 0.05 mcg/kg/min IV as an alternative inotrope-vasopressor, titrated to effect

›Hydrocortisone 50 mg IV every 6 hours for catecholamine-refractory shock

›Monitoring cadence for any vasoactive infusion

›Arterial line in place, mean arterial pressure checked every 1 to 5 minutes during titration

›Lactate every 2 to 4 hours and hourly urine output

Refractory shock and mechanical circulatory support

›Definition of refractory shock in this setting

›Persistent hypoperfusion despite adequate filling and two vasoactive agents

›Rising lactate, falling cardiac output on echocardiography, and worsening acidosis

›Venoarterial extracorporeal membrane oxygenation

›The main salvage therapy for colchicine-induced cardiogenic shock, with survivors reported

›Referral made early, before multi-organ failure and coagulopathy make cannulation hazardous

›Intra-aortic balloon pump is not the preferred device

›The lesion is global myocardial toxicity with a distributive component, not isolated left ventricular afterload mismatch

›It provides insufficient support and should not delay extracorporeal membrane oxygenation referral

›Bradyarrhythmia and high-grade block

›Atropine 0.5 mg IV, then transcutaneous pacing, then transvenous pacing for hemodynamically significant block

›Isoproterenol 0.5 to 10 mcg/min IV infusion as a bridge to pacing

›Therapy-is-not-working escalation

›Re-confirm the diagnosis and exclude tamponade, tension pneumothorax, occult hemorrhage, and untreated hyperkalemia

›Optimize ionized calcium and magnesium, add stress-dose corticosteroid, and escalate to extracorporeal support

Airway, ventilation, and sedation

›Rapid sequence intubation drugs chosen for hemodynamic tolerance

›Ketamine 1 to 2 mg/kg IV as the induction agent

›Pediatric ketamine 1 to 2 mg/kg IV, verify against current pediatric guideline before use

›Etomidate 0.3 mg/kg IV as an alternative, accepting transient adrenal suppression

›Rocuronium 1.2 mg/kg IV as the paralytic of choice

›Pediatric rocuronium 1.2 mg/kg IV, verify against current pediatric guideline before use

›Succinylcholine 1.5 mg/kg IV avoided when hyperkalemia, established rhabdomyolysis, or acute kidney injury is present because it can precipitate lethal hyperkalemia

›Post-intubation sedation

›Fentanyl infusion 0.5 to 2 mcg/kg/h with low-dose midazolam 0.05 mg/kg IV boluses

›Propofol infusion 5 to 50 mcg/kg/min avoided as the primary agent because it deepens hypotension and myocardial depression and adds propofol-related infusion syndrome risk in shocked, catecholamine-supported patients

›Lung-protective ventilation

›Tidal volume 6 ml/kg predicted body weight, plateau pressure below 30 cmH2O

›PaO2 at least 60 mmHg and pH at least 7.20 accepted, with permissive hypercapnia

›Cautious positive pressure

›Preload reduction can unmask hypovolemia, so give a fluid bolus and have a vasopressor ready at induction

Hematologic support, coagulopathy, and rhabdomyolysis

›Bone marrow rescue

›Filgrastim, granulocyte colony-stimulating factor, 5 mcg/kg/day subcutaneously or IV for neutropenia

›Started when the neutrophil count falls and continued until recovery

›Pediatric filgrastim 5 mcg/kg/day, verify against current pediatric guideline before use

›Sargramostim, granulocyte-macrophage colony-stimulating factor, 250 mcg/m2/day where filgrastim is unavailable

›Neutropenic precautions and prompt empirical broad-spectrum antibiotic cover per the institutional febrile neutropenia pathway for any fever

›Transfusion support

›Platelets for a count below 10 x10^9/l, or below 50 x10^9/l with bleeding or before a procedure

›Packed red cells to keep hemoglobin above 70 g/l, higher with active cardiac ischemia

›Fresh frozen plasma 10 to 15 ml/kg and cryoprecipitate for fibrinogen below 1.5 g/l when bleeding

›Disseminated intravascular coagulation

›Treatment is supportive with factor replacement targeted to bleeding, not to numbers alone

›Empirical systemic anticoagulation and antifibrinolytics such as tranexamic acid 1 g IV avoided unless a specific indication emerges

›Vitamin K 10 mg IV for a prolonged prothrombin time with hepatic dysfunction

›Rhabdomyolysis

›Isotonic crystalloid titrated to a urine output of 1 to 2 ml/kg/h

›Serial creatine kinase, potassium, and calcium, with an ECG after each potassium or calcium shift

›Routine urinary alkalinization and mannitol not used, particularly with oliguria or fluid intolerance

Symptom control, interventions to avoid, and ineffective therapies

›Antiemetics chosen with the QT interval in mind

›Ondansetron 4 mg IV every 8 hours at the lowest effective dose, with QT monitoring because colchicine, hypocalcemia, and hypomagnesemia already prolong repolarization

›Metoclopramide 10 mg IV every 6 hours as an alternative, avoided in bowel obstruction

›Analgesia

›Fentanyl 25 to 50 mcg IV titrated, preferred for hemodynamic neutrality

›Morphine 2 to 4 mg IV used cautiously because histamine release and venodilation worsen hypotension

›Nonsteroidal anti-inflammatory drugs such as ibuprofen 400 mg orally avoided because of renal, gastrointestinal, and platelet effects

›Acetaminophen 1 g IV or orally every 6 hours, maximum 4 g/day, reduced to 2 to 3 g/day with hepatic injury

›Iatrogenic-harm review for routine emergency interventions

›Intubation: necessary but peri-intubation arrest is common, so pre-treat with fluid and a vasopressor and use ketamine

›Sedation: propofol infusion deepens shock, so use fentanyl-based sedation

›Fluid loading: life-saving in phase 1 but harmful once capillary leak and cardiomyopathy develop, so reassess continuously

›Oxygen: standard targets, 88 to 92% in known chronic hypercapnic respiratory disease

›Vasopressors: required, but pure vasoconstriction without inotropy can worsen output once the myocardium fails

›Mechanical circulatory support: prefer venoarterial extracorporeal membrane oxygenation over intra-aortic balloon pump

›Anticoagulation: avoided because disseminated intravascular coagulation and thrombocytopenia make bleeding the dominant risk

›Fibrinolysis: no indication and contraindicated with coagulopathy

›Analgesia: fentanyl preferred, nonsteroidal anti-inflammatory drugs avoided, and hepatically cleared agents used with caution

›Ineffective and investigational therapies

›Hemodialysis and hemoperfusion do not remove colchicine and are used only for renal replacement

›Colchicine-specific Fab antibody fragments showed benefit in a single 1995 case report but were never commercialized and are not available

›No vitamin, chelator, or intravenous lipid emulsion therapy has an established role

09Special Populations/sp44

Pregnancy

›Colchicine crosses the placenta

›At therapeutic doses for familial Mediterranean fever it is generally continued in pregnancy under specialist care

›In overdose the dominant fetal threat is maternal shock, hypoxia, and multi-organ failure

›Resuscitation priorities

›Maternal stabilization first, left lateral tilt after mid-pregnancy, and early obstetric involvement

›Mean arterial pressure at least 65 mmHg, recognizing the lower baseline blood pressure of the second trimester

›Continuous fetal monitoring once the fetus is viable and the mother is stabilized

›Drug choices in the critically ill pregnant patient

›Norepinephrine, ketamine, and rocuronium are acceptable for resuscitation

›Activated charcoal 1 g/kg, maximum 50 g, is unchanged in pregnancy

›Disposition

›Maternal-fetal medicine and toxicology co-management

›Delivery planning only for obstetric indications or maternal instability

Geriatric

›Higher baseline risk at any ingested dose

›Reduced renal reserve, low muscle mass masking a rise in creatinine, and frequent polypharmacy

›Chronic colchicine for gout plus a new CYP3A4 or P-glycoprotein inhibitor is the classic therapeutic-dose disaster

›Assessment

›Full medication reconciliation including recent antibiotics, antifungals, and calcium channel blockers

›Baseline cognition and functional status recorded to interpret later encephalopathy

›Management adjustments

›Smaller crystalloid boluses of 250 ml with earlier ultrasound reassessment given diastolic dysfunction

›Mean arterial pressure target 75 to 85 mmHg where there is long-standing hypertension

›Careful renal dose adjustment and avoidance of nephrotoxins

›Goals of care

›Early discussion where frailty and comorbidity make extracorporeal support inappropriate

10Background/b49

Epidemiology

›Colchicine poisoning is uncommon but carries a high case fatality relative to other drug overdoses

›Most exposures reported to poison centers are minor, but severe ingestions have historically killed a large fraction of those affected

›Mortality is around 10% for ingestions of 0.5 to 0.8 mg/kg and frequently exceeds 50% above 0.8 mg/kg

›Ingestions below 0.5 mg/kg usually cause gastrointestinal symptoms only, with death unusual

›Populations at risk

›Adults with gout, familial Mediterranean fever, pericarditis, or Behcet disease who keep the drug at home

›Young children with unintentional access to a relative's supply

›Patients on chronic colchicine who are newly prescribed an interacting CYP3A4 or P-glycoprotein inhibitor

›Dose reference points

›The acute gout regimen is 1.2 mg then 0.6 mg one hour later, a 1.8 mg total over one hour

›Prophylaxis is 0.6 mg once or twice daily

›Fatalities have followed both large single overdoses and smaller ingestions in the presence of renal failure or interacting drugs

›Exposure setting

›Most deaths involve intentional self-poisoning

›Plant sources such as autumn crocus and glory lily produce an identical toxidrome

Pathophysiology

›Mechanism of toxicity

›Colchicine binds tubulin and prevents microtubule polymerization

›Mitosis arrests in metaphase and intracellular transport, secretion, and cell structure fail

›Rapidly dividing tissues, the gut mucosa and bone marrow, are injured first

›Multi-system consequences

›Massive gastrointestinal fluid and protein loss drives early hypovolemic and distributive shock

›Direct myocardial toxicity produces a dilated, hypokinetic ventricle and conduction disease

›Increased vascular permeability causes acute respiratory distress syndrome

›Marrow arrest causes pancytopenia with a nadir at day 4 to 7

›Skeletal muscle injury, hepatocellular injury, acute kidney injury, disseminated intravascular coagulation, and encephalopathy follow

›Pharmacokinetics relevant to management

11Patient Discharge Instructions/pdi32

When discharge is appropriate

›Discharge considered only when all of the following are met

›A reliable history of an ingestion below 0.5 mg/kg

›A monitored observation period of at least 8 to 12 hours from ingestion with no gastrointestinal symptoms

›Normal repeat full blood count, renal function, electrolytes, calcium, and ECG

›Not eligible for discharge

›Any vomiting, diarrhea, or abdominal pain attributable to colchicine

›Any abnormal vital sign, laboratory value, or ECG change

›Intentional ingestion before psychiatric assessment

›Chronic colchicine use with a newly started interacting drug

›Safety netting before discharge

›A responsible adult to observe the patient for the next 48 hours

›Written return advice and a scheduled follow-up appointment

copy discharge instructions

›Why you are being given this advice

›You took an amount of colchicine that we judge to be low risk, and your tests and monitoring have been normal

›Colchicine poisoning can be delayed, so you must watch for the warning signs below over the next 3 days

›Go to an emergency department immediately, by ambulance, if any of these occur

›Vomiting, watery or bloody diarrhea, or worsening abdominal pain

›Feeling faint, a racing or irregular heartbeat, chest pain, or breathlessness

›A temperature above 38 degrees Celsius, sore throat, mouth ulcers, or any other sign of infection

›Unusual bruising, bleeding gums, blood in the urine or stool, or small red spots on the skin

›Muscle weakness, dark brown urine, passing much less urine than usual, or severe muscle pain

›Confusion, extreme drowsiness, or new numbness and tingling

›Medication advice

›Do not take any more colchicine until your own doctor reviews it

›Do not take anti-diarrhea medicines such as loperamide

›Do not take ibuprofen or other anti-inflammatory painkillers

12References/r18

Guidelines and toxicology references

›American College of Rheumatology Guideline for the Management of Gout, 2020

›Source of the acute gout regimen of 1.2 mg then 0.6 mg one hour later and of low-dose prophylaxis

›EULAR recommendations for the management of familial Mediterranean fever, 2016

›Chronic colchicine dosing and the importance of adherence and drug-interaction awareness

›United States Food and Drug Administration colchicine labeling revision, 2009

›Established reduced-dose regimens with CYP3A4 and P-glycoprotein inhibitors and in renal impairment

›American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists position statements on single-dose and multiple-dose activated charcoal

›Framework for charcoal indication, timing, and airway precautions

›Goldfrank's Toxicologic Emergencies, colchicine and antimitotics chapter, current edition

›Reference synthesis of dose-related prognosis, the phased clinical course, and supportive management

Landmark reports and case literature

›Baud FJ and colleagues, New England Journal of Medicine, 1995

›Single case of severe colchicine poisoning treated with goat-derived colchicine-specific Fab fragments with recovery; the product was never commercialized

›Finkelstein Y and colleagues, Clinical Toxicology, 2010, review of colchicine poisoning

›Summary of mechanism, the three-phase course, dose-related mortality, and supportive treatment

›Dose-prognosis bands from the Paris toxicology group, Bismuth and colleagues

›Origin of the below 0.5, 0.5 to 0.8, and above 0.8 mg/kg mortality stratification still used at the bedside

›Published case reports of venoarterial extracorporeal membrane oxygenation for colchicine-induced cardiogenic shock

›Describe survival after refractory cardiovascular collapse bridged with extracorporeal support

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.